Low Vitamin B12 and Cardiovascular Health: What the Clinical Evidence Actually Shows

Low concentrations of vitamin B12 have frequently been observed in association with cardiovascular disease, sparking widespread interest in whether dietary supplements might offer protection for the heart and blood vessels. A recent narrative review published in the Nutrition Journal examines laboratory data, large population studies, and clinical trials to evaluate the complex relationship between vitamin B12 status and cardiovascular outcomes. While observational research highlights clear links between deficiency and vascular risks, clinical trials tell a more nuanced story regarding supplementation.

Mechanisms Linking B12 Deficiency to Vascular Risk

Researchers have outlined several biological pathways through which a shortage of vitamin B12 could potentially harm the cardiovascular system. Vitamin B12 is essential for key enzymatic functions, including the conversion of the amino acid homocysteine into methionine. When B12 levels are inadequate, homocysteine and methylmalonic acid accumulate in the body.

Elevated homocysteine, known as hyperhomocysteinemia, is associated with endothelial dysfunction, a condition where blood vessels fail to dilate properly in response to increased blood flow. Animal studies cited in the review demonstrated increased plaque accumulation alongside elevated homocysteine levels, while human observations in postmenopausal women linked hyperhomocysteinemia to impaired flow-mediated dilation. Furthermore, vitamin B12 deficiency can induce a methyl-folate trap, impairing DNA synthesis and reducing the availability of primary methyl donors necessary for normal gene regulation in blood walls.

What Clinical Trials Reveal About Supplementation

Despite the plausible mechanisms connecting low B12 to vascular damage, randomized controlled trials have generally failed to show that B-vitamin supplementation consistently prevents major cardiovascular events like heart attacks or cardiovascular deaths. Large-scale investigations, such as the NORVIT and HOPE-2 trials, successfully lowered homocysteine levels using combined B-vitamin regimens containing folic acid and B12, but these interventions did not produce a uniform reduction in coronary heart events.

A Cochrane review encompassing more than 71,000 participants similarly found no meaningful overall benefit for coronary outcomes from homocysteine-lowering vitamin therapies. However, pooled trial data did reveal an approximate 10 percent relative reduction in stroke incidence. This protective signal against stroke was particularly pronounced in regions without mandatory folic acid fortification, where subgroup analyses showed a 30 to 35 percent relative drop in stroke events among participants who also presented with low baseline folate levels.

High-Risk Groups and Diagnostic Considerations

Certain populations face a heightened risk of developing a vitamin B12 deficiency:

• Older adults, due to age-related reductions in stomach acid and poorer intestinal absorption.
• Vegetarians and vegans, as natural B12 is predominantly found in animal-derived foods.
• Individuals who have undergone bariatric surgery, requiring long-term monitoring because liver stores can mask deficiency for years.
• Patients with chronic kidney disease on dialysis, who frequently experience elevated homocysteine.

Medical experts note that routine population-wide screening for B12 to prevent heart disease is not currently recommended. Standard blood tests measure total B12, which includes inactive forms that cells cannot utilize. When results are borderline, clinicians often evaluate specific markers like methylmalonic acid or holotranscobalamin to confirm a functional deficiency. While correcting a confirmed B12 deficiency provides established benefits for neurological and hematologic health, current evidence does not support high-dose B12 supplementation as a standalone cardioprotective measure.